Brokers Set Expectations for Pain Therapeutics, Inc.’s FY2021 Earnings (PTIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) – Gabelli issued their FY2021 EPS estimates for shares of Pain Therapeutics in a research note issued on Thursday, Zacks Investment Research reports. Gabelli analyst K. Kedra forecasts that the biopharmaceutical company will post earnings of ($0.35) per share for the year.

TRADEMARK VIOLATION WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/04/21/brokers-set-expectations-for-pain-therapeutics-inc-s-fy2021-earnings-ptie-updated-updated.html.

Shares of Pain Therapeutics (NASDAQ:PTIE) traded down 1.3384% during trading on Friday, reaching $0.7814. The company’s stock had a trading volume of 244,263 shares. The company’s market capitalization is $36.05 million. The firm’s 50-day moving average price is $0.78 and its 200-day moving average price is $0.67. Pain Therapeutics has a one year low of $0.51 and a one year high of $3.00.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Gabelli Funds LLC increased its position in shares of Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares in the last quarter. Spark Investment Management LLC purchased a new position in shares of Pain Therapeutics during the third quarter valued at $119,000. Acadian Asset Management LLC increased its position in shares of Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 92,358 shares in the last quarter. Finally, BVF Inc. IL increased its position in shares of Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock valued at $2,278,000 after buying an additional 128,639 shares in the last quarter. 44.34% of the stock is owned by institutional investors.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

5 Day Chart for NASDAQ:PTIE

Get a free copy of the Zacks research report on Pain Therapeutics (PTIE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply